This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Hooge, A. S. K. Articles by van den Berg, W. B. Search for Related Content PubMed PubMed Citation Articles by de Hooge, A. S. K. Articles by van den Berg, W. B.

(American Journal of Pathology. 2002;160:1733-1743.)
© 2002 American Society for Investigative Pathology

Regular Articles

Adenoviral Transfer of Murine Oncostatin M Elicits Periosteal Bone Apposition in Knee Joints of Mice, Despite Synovial Inflammation and Up-Regulated Expression of Interleukin-6 and Receptor Activator of Nuclear Factor-B Ligand

Alfons S. K. de Hooge^*, Fons A. J. van de Loo^*, Miranda B. Bennink^*, Diana S. de Jong, Onno J. Arntz^*, Erik Lubberts^*, Carl D. Richards and Wim B. van den Berg^*

From the Rheumatology Research Laboratory,^*University Medical Center Nijmegen, Nijmegen, The Netherlands; Applied Biology,Catholic University Nijmegen, Nijmegen, The Netherlands; and the Department of Pathology and Molecular Medicine,McMaster University, Hamilton, Ontario, Canada

Oncostatin M (OSM) has been described as a bone-remodeling factor either stimulating osteoblast activity or osteoclast formation in vitro. To elucidate the in vivo effect of OSM on bone remodeling, we injected an adenoviral vector encoding murine OSM in knee joints of mice. OSM strongly induced interleukin (IL)-6 gene expression, a known mediator of osteoclast development. We investigated the OSM effect in wild-type and IL-6-deficient mice and found a similar degree of OSM-induced joint inflammation. Within the first week of inflammation, the periosteum along the femur and tibia increased in cell number and stained positive for the osteoblast marker alkaline phosphatase. At these sites bone apposition occurred in both strains as demonstrated by Goldner and Von Kossa staining. In vitro OSM enhanced the effect of bone morphogenetic protein-2 on osteoblast differentiation. Immunohistochemistry demonstrated expression of receptor activator of nuclear factor-B ligand (RANKL) and its receptor, receptor activator of nuclear factor-B (RANK), in the periosteum but osteoclasts were not detected at sites of bone apposition. Induced mRNA expression for the receptor activator of nuclear factor-B ligand inhibitor osteoprotegerin probably controlled osteoclast development during OSM overexpression. Our results show that OSM favors bone apposition at periosteal sites instead of resorption in vivo. This effect was not dependent on or inhibited by IL-6.

This article has been cited by other articles:

				B. Brounais, C. Chipoy, K. Mori, C. Charrier, S. Battaglia, P. Pilet, C. D. Richards, D. Heymann, F. Redini, and F. Blanchard Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo Clin. Cancer Res., September 1, 2008; 14(17): 5400 - 5409. [Abstract] [Full Text] [PDF]

				J. P. Conway and M. Kinter Proteomic and Transcriptomic Analyses of Macrophages with an Increased Resistance to Oxidized Low Density Lipoprotein (oxLDL)-induced Cytotoxicity Generated by Chronic Exposure to oxLDL Mol. Cell. Proteomics, October 1, 2005; 4(10): 1522 - 1540. [Abstract] [Full Text] [PDF]

				A. D. Rowan, W. Hui, T. E. Cawston, and C. D. Richards Adenoviral Gene Transfer of Interleukin-1 in Combination with Oncostatin M Induces Significant Joint Damage in a Murine Model Am. J. Pathol., June 1, 2003; 162(6): 1975 - 1984. [Abstract] [Full Text] [PDF]